Related Experiment Videos
Physiologic basis of dyskinesia.
1Department of Anatomy and Physiology, Faculty of Medicine, Laval University, CHUL Research Center, Quebec, Canada.
Annals of Neurology
|April 13, 2000
Summary
Dyskinesia may stem from disrupted neuronal response selection, not just low basal ganglia output. Imbalances in dopamine and cortical-thalamic signaling contribute to movement disorders.
Area of Science:
- Neuroscience
- Movement Disorders
- Neuropharmacology
Background:
- The traditional basal ganglia model attributes dyskinesia to reduced output activity.
- Emerging evidence suggests other mechanisms, including impaired surround inhibition, are critical.
- Dopamine's role in reward prediction and its presynaptic control are key factors.
Purpose of the Study:
- To explore alternative mechanisms contributing to dyskinesia beyond the established functional model.
- To investigate the role of surround inhibition and dopamine release in basal ganglia function.
- To analyze the influence of cortical and thalamic afferents on basal ganglia pathways.
Main Methods:
- Review of recent literature on basal ganglia function and dyskinesia.
- Analysis of the physiological mechanisms of surround inhibition.
- Examination of dopamine's presynaptic control and its implications for levodopa therapy.
- Evaluation of the distinct roles of cortical and thalamic inputs to the striatum.
Main Results:
- Dyskinesia may arise from disturbed surround inhibition, a mechanism for neuronal selection.
- Levodopa may exacerbate imbalances in dopaminergic terminal distribution within the basal ganglia.
- Cortical and thalamic pathways differentially influence striatal projection neurons, impacting information selection and attention.
Conclusions:
- The functional model of basal ganglia requires expansion to include surround inhibition and afferent pathway dynamics.
- Imbalances between cortical (selection) and thalamic (attention) influences may underlie dyskinesia.
- Understanding these complex interactions is crucial for developing targeted therapies for movement disorders.